Terms: = Germ cell tumor AND FCGR2B, FCGR2, 2213, ENSG00000072694, CD32, CD32B, P31994, IGFR2, FCG2 AND Treatment
6 results:
1. fcgr2b as a prognostic and immune microenvironmental marker for gliomas based on transcriptomic analysis.
Sun Z; Sun X; Yuan Y; Li H; Li X; Yao Z
Medicine (Baltimore); 2023 Sep; 102(37):e35084. PubMed ID: 37713871
[TBL] [Abstract] [Full Text] [Related]
2. Association of treatment Facility Characteristics With Overall Survival After Mohs Micrographic Surgery for T1a-T2a Invasive Melanoma.
Cheraghlou S; Christensen SR; Leffell DJ; Girardi M
JAMA Dermatol; 2021 May; 157(5):531-539. PubMed ID: 33787836
[TBL] [Abstract] [Full Text] [Related]
3. Gene expression-based biomarkers designating glioblastomas resistant to multiple treatment strategies.
Menyhárt O; Fekete JT; Győrffy B
Carcinogenesis; 2021 Jun; 42(6):804-813. PubMed ID: 33754151
[TBL] [Abstract] [Full Text] [Related]
4. Talimogene Laherparepvec for the treatment of Advanced Melanoma.
Ott PA; Hodi FS
Clin Cancer Res; 2016 Jul; 22(13):3127-31. PubMed ID: 27146699
[TBL] [Abstract] [Full Text] [Related]
5. Natural history and outcome in Chinese patients with gastroenteropancreatic neuroendocrine tumours: - a 17-year retrospective analysis.
Chan DT; Luk AO; So WY; Kong AP; Chow FC; Ma RC; Lo AW
BMC Endocr Disord; 2016 Feb; 16():12. PubMed ID: 26911576
[TBL] [Abstract] [Full Text] [Related]
6. A multi-factorial genetic model for prognostic assessment of high risk melanoma patients receiving adjuvant interferon.
Wang E; Zhao Y; Monaco A; Uccellini L; Kirkwood JM; Spyropoulou-Vlachou M; Panelli MC; Marincola FM; Gogas H
PLoS One; 2012; 7(7):e40805. PubMed ID: 22911710
[TBL] [Abstract] [Full Text] [Related]
